ONCOLYTICS BIOTECH (NASDAQ: ONCY) CTO awarded 260,000 stock options at $1.06 strike

Rhea-AI Filing Summary

ONCOLYTICS BIOTECH INC reported that Chief Technology Officer Allison Hagerman received a grant of stock options covering 260,000 Common Shares. The options have an exercise price of $1.06 per share, matching the Nasdaq Capital Market closing price on June 1, 2026, and expire on June 1, 2036.

The award vests in three equal annual installments, with the first tranche vesting on June 1, 2027, conditioned on continued service or employment. Following this grant, Hagerman holds 260,000 stock options directly, and the filing does not show any share purchases or sales.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hagerman Allison

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	260,000	$0.00	--

Holdings After Transaction: Stock Option — 260,000 shares (Direct, null)

Footnotes (1)

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Key Figures

Stock options granted: 260,000 options Exercise price: $1.06 per share Expiration date: June 1, 2036 +3 more

6 metrics

Stock options granted 260,000 options Grant to CTO Allison Hagerman for Common Shares

Exercise price $1.06 per share Equal to Nasdaq closing price on June 1, 2026

Expiration date June 1, 2036 Option term from grant date

Underlying shares 260,000 Common Shares Shares subject to the stock option grant

Post-grant derivative holdings 260,000 options Total stock options held following transaction

Vesting schedule 3 equal annual installments First tranche vests June 1, 2027

Key Terms

Stock Option, exercise price, vesting, expiration date, +1 more

5 terms

Stock Option financial

"The reporting person received a grant of Stock Option covering 260,000 Common Shares."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"The stock option has an expiration date of June 1, 2036."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"The transaction code description is Grant, award, or other acquisition."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hagerman Allison

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.06(1)	06/01/2026		A		260,000		(2)	06/01/2036	Common Shares	260,000	$0	260,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

	/s/ Kirk Look, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ONCY Chief Technology Officer Allison Hagerman receive in this Form 4?

Allison Hagerman received a grant of stock options for 260,000 Common Shares. These options are a form of equity compensation that give her the right to buy ONCOLYTICS BIOTECH INC shares at a fixed exercise price in the future.

What is the exercise price of Allison Hagerman’s ONCY stock options?

The options have an exercise price of $1.06 per share, equal to the Nasdaq Capital Market closing price on June 1, 2026. This means she can buy shares at $1.06 once the options vest and are exercised.

When do Allison Hagerman’s ONCY stock options vest and expire?

The 260,000 stock options vest in three equal annual installments, starting on June 1, 2027. They expire on June 1, 2036, giving a 10-year window from the grant date to exercise the options after they vest.

Did Allison Hagerman buy or sell ONCY common shares in this filing?

No, this Form 4 only reports a grant of stock options classified as an acquisition under code A. It does not show any open-market purchases or sales of ONCOLYTICS BIOTECH INC common shares by Hagerman on the reported date.

How many ONCY stock options does Allison Hagerman hold after this grant?

Following this transaction, Hagerman is reported as holding 260,000 stock options directly. Each option corresponds to one underlying Common Share, so the grant represents potential future rights to acquire 260,000 ONCOLYTICS BIOTECH INC shares if exercised.